Q3 2024 Bergenbio ASA Earnings Call TranscriptNov 13, 2024kr6.4 (-11.92%)Earnings- Q2 2024 Bergenbio ASA Earnings Call TranscriptAug 21, 2024kr11.7Earnings
- Q1 2024 Bergenbio ASA Earnings Call TranscriptMay 29, 2024kr14.28 (-0.97%)Earnings
- Q3 2023 Bergenbio ASA Earnings Call TranscriptNov 14, 2023kr18.14 (-3.41%)Earnings
- Q2 2023 Bergenbio ASA Earnings Call TranscriptAug 23, 2023kr10.88 (+13.10%)Earnings
- Q4 2022 Bergenbio ASA Earnings Call TranscriptFeb 16, 2023kr350.52Earnings
- Q3 2022 Bergenbio ASA Earnings Call TranscriptNov 15, 2022kr392.21 (-3.46%)Earnings
- Q2 2022 Bergenbio ASA Earnings Call TranscriptAug 23, 2022kr598.6 (-7.60%)Earnings
- Q1 2022 Bergenbio ASA Earnings Call TranscriptMay 24, 2022kr787.93 (-4.21%)Earnings
- Bergenbio ASA Strategy Update TranscriptMay 04, 2022
- Q4 2021 Bergenbio ASA Earnings Call TranscriptFeb 16, 2022kr864.26 (-4.50%)Earnings
- Q3 2021 Bergenbio ASA Earnings Call TranscriptNov 16, 2021kr1040.23 (+3.16%)Earnings
- Q2 2021 Bergenbio ASA Earnings Call TranscriptAug 17, 2021kr1130.92 (-5.41%)Earnings
- Q1 2021 Bergenbio ASA Earnings Call TranscriptMay 19, 2021kr1172.1 (-9.39%)Earnings
- Bergenbio ASA to Discuss Top Line Data From Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients Call TranscriptMay 18, 2021
- Q4 2020 Bergenbio ASA Earnings Call TranscriptFeb 10, 2021kr1680.9 (-4.09%)Earnings
- Q3 2020 Bergenbio ASA Earnings Call TranscriptNov 17, 2020kr1408.59 (-3.60%)Earnings
- Q2 2020 Bergenbio ASA Earnings Call TranscriptAug 18, 2020kr1817.9Earnings
- Q1 2020 Bergenbio ASA Earnings Call TranscriptMay 19, 2020kr1998.69 (-7.01%)Earnings
- Q4 2019 Bergenbio ASA Earnings Call TranscriptFeb 11, 2020kr882.67Earnings
Q2 2023 Bergenbio ASA Earnings Call Transcript
Good morning, and welcome. I'm Martin Olin, the CEO of BerGenBio. I'm pleased to provide you with our Q2 2023 report. Just remind the audience about the formalities.
So BerGenBio in a nutshell, we consider ourselves to be the world leader in AXL biology. And we know that AXL biology is important. It's known to play a key role in the progression of several diseases, including cancer, respiratory diseases, and fibrosis.
We have two proprietary, which means our own, clinical stage program: bemcentinib, a small molecule, which is our lead program; and tilvestamab, a monoclonal antibody. In multiple Phase 2 trials, we have shown that the relevance of bemcentinib is quite important as it confers to clinical benefits in non-small-cell lung cancer, in AML, in MDS, and mesothelioma. And the data all points to the same direction, that bemcentinib actually leads to an increased progression-free survival, but also overall survival for these patients across these diseases. So this is quite interesting.
We are, however, focusing the development of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
